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The three-dimensional fold of Plasmodium falciparum (Pf) 20S proteasome is similar to yeast Saccharomyces
cerevisiae 20S proteasome. The twenty eight subunits complex corresponding to two copies of seven distinct α and
seven distinct β subunits shares >35% sequence identity with equivalent subunits of the yeast 20S proteasome.
Bortezomib (Velcade®) – a known inhibitor of the three catalytic subunits; β1, β2, β5 of the yeast 20S proteasome
can bind in the equivalent subunits of the Pf 20S proteasome and is in agreement with experimental results. The
model defines the binding mode of the bortezomib inhibitor within the catalytic subunits of the Pf 20S proteasome
and provides the structural basis for the design of Pf 20S proteasome-specific inhibitors. The substitutions associated
within the catalytic subunits of Pf 20S proteasome relative to yeast 20S proteasome; Thr21-Ser, Thr22-Ser, Thr31-Ser,
Thr35-Asn, Ala49-Ser (in β1 subunit), Ser20-Ala, Gln22-Glu (β2) and Thr21-Ser, Ala22-Met, Gln53-Leu (β5) may influence
the relative caspase-like, tryptic-like and chymotryptic-like activities of the Pf 20S proteasome. The plasmodia-specific
‘large’ insert comprising fifty four amino acid residues (in β1 subunit) of the Pf 20S proteasome is distant from the
catalytic sites.
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An essential element of the protein quality control
machinery in cells is the ubiquitin-proteasomal system
(Hershko & Ciechanover 1998; Pickart 2001; Myung et al.
2001). Proteasomes (Wolf & Hilt 2004) are protein de-
gradative machines found in the nucleus and cytoplasm of
all eukaryotic organisms and archaebacteria and is a highly
organized protease complex comprising a catalytic 20S
core particle (CP) and two 19S regulatory particles (RP),
which together form the 26S structure. The core particle
degrading machinery in yeast Saccharomyces cerevisiae
20S proteasome is coded by fourteen genes and two copies
of these constitute the twenty eight subunits in the com-
plex. The 26S proteasome multi-subunits complex is the
final destination for selective degradation of majority of
cellular proteins and is responsible for the degradation of
most ubiquitylated proteins through a multistep process* Correspondence: guru@ccmb.res.in
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in any medium, provided the original work is pinvolving recognition of the polyubiquitin chain, unfolding
of the substrate, and translocation of the substrate into the
active site in the cavity of the CP. The structure, function,
assembly and catalytic mechanism of the proteasome are
reviewed in (Jung & Grune 2012; Saeki & Tanaka 2012;
Coux et al. 1996; Marques et al. 2009). The crystal
structures of yeast 20S proteaseome (Groll et al. 1997)
and bovine 20S proteasome (Unno et al. 2002) are avail-
able in the Protein Data Bank (PDB) (Rose et al. 2013).
The crystal structure of the core particle in eukaryotic
yeast Saccharomyces cerevisiae, has a barrel-shaped cylin-
drical structure that is comprised of four heptameric rings
(α1-7β1-7β1-7α1-7), in which each subunit is different from
the other and individual subunits are uniquely located in
the three-dimensional structure of the complex (Groll
et al. 1997). The α-ring on the outer sides functions as a
gate for the substrate to enter while the β-ring has the
proteolytic activity. In yeast 20S proteasome, the β1, β2
and β5 subunits are known to possess catalytic activity,
where β1 subunit mediates the peptidyl-glutamyl peptidean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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the post-basic (trypsin-like) activity and the β5 subunit
post-hydrophobic (chymotrypsin-like) activity (Arendt &
Hochstrasser 1997; Heinemeyer et al. 1997). The protea-
somes share the fold and a novel catalytic mechanism with
an N-terminal nucleophilic threonine and therefore placed
in the family of Ntn (N terminal nucleophile) hydrolases
(Bochtler et al. 1999). The crystal structure of bovine
20S proteasome revealed an additional novel catalytic
subunit – the β7 subunit (Unno et al. 2002). In addition
to the 20S core proteasome, the yeast 26S proteasome
comprises two regulatory subcomplexes containing
nineteen subunits (referred as 19S regulatory complex);
six Rpt (Regulatory particle ATPases) and thirteen RPN
(Regulatory particle Non-Atpases) attached at terminal
ends of the central portion and in opposite orientations
(DeMartino & Slaughter 1999; Voges et al. 1999). The
complete subunit architecture of the yeast regulatory
particle provides a model for the recognition, deubiquiti-
nation and engagement of a polyubiquitinated substrate
by the 26S proteasome (Lander et al. 2012). The molecular
architecture of the 26S holocomplex has been determined
by an integrative approach based on data from cryoelec-
tron microscopy, X-ray crystallography, residue-specific
chemical cross-linking, and several proteomic techniques
(Lasker et al. 2012; Förster et al. 2010; Nickell et al. 2009).
Proteasomes are central to many cellular processes as they
are responsible for the cytoplasmic turnover of a number
of proteins and therefore manipulating the proteasomal
activity is considered a key goal in controlling the stability
of regulatory proteins (Groll & Huber 2004; Kisselev &
Goldberg 2001). The observation that proteasome in-
hibitors cause apoptosis in certain tumor-derived cell
lines has led to their application as potential cancer
therapeutics (Adams et al. 1998). Bortezomib (Velcade®)
has been approved for treatment of multiple mye-
loma patients (Ludwig et al. 2005; Richardson et al.
2005; Teicher et al. 1999). The proteasome is a poten-
tial target for treating many infections and diseases
(Dahlmann 2007).
In plasmodia two T1 threonine peptidase systems are
known to be present; the 20S proteasome is enzymati-
cally active and expressed throughout the live cycle,
whereas the PfhsIV is expressed in late stages of devel-
opment only (Mordmüller et al. 2006). The emergence
and spread of Plasmodium falciparum resistance to al-
most all available antimalarial drugs has necessitated
the search for new chemotherapeutic compounds. It
has been shown that the 20S proteasome is expressed
and catalytically active in plasmodia and treatment with
proteasome inhibitors arrests parasite growth and
therefore inhibition of the proteasome is considered to
be a highly promising strategy to develop new antima-
larials (Kreidenweiss et al. 2008).A three-dimensional model of the twenty eight sub-
units complex corresponding to the core particle (CP) of
Plasmodium falciparum (Pf ) is currently not available,
although individual models for twelve of the fourteen
genes of the CP are available in the ModBase database
(Pieper et al. 2011). Bortezomib, a peptide boronate, is
the only proteasome inhibitor in clinical use so far. In
contrast to multiple myeloma treatment (Rajkumar et al.
2005), its activity in P. falciparum laboratory strains is
low (Kreidenweiss et al. 2008). The crystal structure of
yeast 20S proteasome bound to bortezomib (Groll et al.
2006) is available in the PDB. Therefore, in order to
evaluate the mode and affinity of binding of the bortezo-
mib inhibitor within the equivalent catalytic subunits of
the Pf 20S proteasome, we have constructed a three-
dimensional model based on the crystal structures of the
homologous yeast and bovine 20S proteasomes and
docked bortezomib within the catalytic subunits of the
Pf 20S proteasome model. Further, we have identified
substitutions within the catalytic subunits of the Pf 20S
proteasome relative to the yeast 20S proteasome. Our
models of the Pf 20S proteasome complexed with the
bortezomib inhibitor provide a structural basis for fur-
ther design of Pf 20S proteasome-specific inhibitors that
has implications for the treatment of malaria.
Materials and methods
Selection and identification of Pf 20S proteasome subunit
sequences
The Pf proteasome subunit sequence codes were se-
lected from the PlasmoDB database (Aurrecoechea
et al. 2009). Their equivalent codes from the UniProt
database (The UniProt Consortium 2010) were also
identified. The homologs of these subunits correspond-
ing to proteins of known three-dimensional structure
were identified from the PDB using the PSI-BLAST pro-
gram (Altschul et al. 1997).
Construction & validation of the Pf 20S proteasome and
docking of bortezomib within the catalytic subunits
The crystal structures of the yeast 20S proteasome
(PDB code:1RYP) (Groll et al. 1997) and bovine 20S
proteasome (PDB code:1IRU) (Unno et al. 2002) were
used as templates in the comparative protein modeling
software program MODELER (Eswar et al. 2008) for
constructing a three-dimensional model of the Pf 20S
proteasome. The individual Pf 20S proteasome subunit
sequences were aligned along with their equivalent se-
quences in yeast and bovine 20S proteasomes. MOD-
ELER constructs a 3-D model for the query sequence
using sequence-to-template alignment and the satisfac-
tion of spatial restraints derived from the template
structure(s) (Sali & Blundell 1993). The overall quality
of the protein model was evaluated using the PROCHECK
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using PyMol http://sourceforge.net/projects/pymol/. The
docking of bortezomib inhibitor was carried out using Auto-
Dock (Morris et al. 2009). In order to validate our docking
studies, the coordinates of bortezomib was removed from
the crystal structure of the yeast 20S proteasome (PDB code:
2F16). A model of the yeast 20S proteasome with bortezo-
mib docked within the catalytic subunits using AutoDock
was generated. The docked complex was structurally super-
imposed on to the crystal structure complex of yeast 20S
proteasome with bound bortezomib in the three catalytic
subunits; β1, β2 and β5 (PDB code: 2F16). The binding
mode of bortezomib and inter-molecular interaction ener-
gies within the three catalytic subunits of the yeast 20S pro-
teasome were evaluated. Upon successfully reproducing the
bortezomib binding in the yeast 20S proteasome, bortezo-
mib was then docked in the equivalent catalytic subunits of
the Pf 20S proteasome model. The binding mode and inter-
molecular interaction energies were once again evaluated
and compared with results obtained for bortezomib binding
in the yeast 20S proteasome.Comparison of the catalytic sites, substrate binding
pockets and bortezomib binding in 3-D models of Pf
20S proteasome and crystal structure complex of yeast
20S proteasome
The residues important for the catalytic activity, sub-
strate binding pockets and maintenance of stability of
the conformation of Thr1 via hydrogen bond essential
for the Ntn hydrolases was obtained from the crystalTable 1 Plasmodium falciparum 20S proteasome subunit seq
PlasmoDB IDs
S.No. UniProt accession codes
for Pf20S proteasome
sequences
PDB chains corresponding to
yeast homologous subunits for




1 Q8I261 1RYP/J/X 1IRU/J
2 Q8IDG3 1RYP/C/Q 1IRU/C
3 Q8IDG2 1RYP/D/R 1 IRU
4 Q8IJT1 1RYP/L/Z 1 IRU
5 Q7K6A9 1RYP/N/2 1 IRU
6 C6KST3 1RYP/B/P 1 IRU
7 Q8I6T3 1RYP/I/W 1 IRU
8 Q8IBI3 1RYP/E/S 1 IRU
9 Q8IK90 1RYP/F/T 1 IRU
10 Q8IKC9 1RYP/K/Y 1 IRU
11 Q8IAR3 1RYP/A/O 1 IRU
12 C0H4E8 1RYP/M/1 1 IRU
13 Q8I0U7 1RYP/H/V 1 IRU
14 O77396 1RYP/G/U 1 IRU
PDB chains corresponding to homologs of yeast and bovine 20S proteasome subunstructure of the yeast 20S proteasome (PDB code:
1RYP). Further, the interactions made by the bortezo-
mib inhibitor in the catalytic subunits of the yeast 20S
proteasome were obtained from (Groll et al. 2006) and
LigPlot diagrams (Wallace et al. 1995) for the crystal
structure of the yeast 20S proteasome with bortezomib
inhibitor (PDB code:2F16). The amino acid sequences
corresponding to the individual catalytic subunits from
yeast, bovine and Pf 20S proteasomes were aligned using
the CLUSTALW program (Thompson et al. 1994). The
molecular graphics software spdview (Guex & Peitsch
1997) was used to generate the hydrogen-bond interac-
tions between the bortezomib inhibitor and residues in
the binding pockets of the yeast and Pf 20S proteasomes.Results and discussion
The accession codes corresponding to the individual
subunit sequences of Pf 20S proteasome are shown in
Table 1. The homologous chains in yeast and bovine 20S
proteasomes and the ModBase IDs corresponding to 3-D
models available for subunits are listed.
The Pf 20S proteasome subunit sequences share > 35%
sequence identity with equivalent subunits in yeast and bo-
vine 20S proteasomes. Certain regions excluded in the
model and listed in Table 2, mainly correspond to the N-
terminal regions of the catalytic β-subunits. These regions
are processed at the Gly-Thr1 site during the formation of
the active core proteasome. Further, the β1 and β7 subunits
comprise certain ‘large’ insertions in the middle of the sub-
unit sequences and these were also excluded in the modeluences, UniProt accession codes and equivalent
hains corresponding to








/X PF3D7_0108000 PFA0400c 3202
/Q PF3D7_1353800 No model
/D/R PF3D7_1353900 MAL13P1.270 185
/L/Z PF3D7_1011400 PF10_0111 1187
/N/2 PF3D7_0803800 MAL8P1.142 660
/B/P PF3D7_0608500 TR Q7RK69
/I/W PF3D7_1328100 PF13_0156 2140
/E/S PF3D7_0727400 PF07_0112 912




/H/V PF3D7_0931800 No model
/G/U PF3D7_0317000 PFC0745c 3667
its and the ModBase IDs for individual Pf 20S proteasomal subunit models.
Table 2 Excluded regions in the Pf 20S model and their
corresponding subunits









1 Q8IJT1 MVIAS…..DFHKG (N-ter) 60
2 Q7K6A9 NSQKYD…..EYKEI (middle) 35
3 Q8I6T3 MKLEY…..FRKTG (N-ter) 41
4 Q8IBI3 MFSTRSEY (N-ter) 8
IDMTA (C-ter) 5
5 Q8IAR3 MVRPSQ (N-ter) 6
6 C0H4E8 MDLIL.....GRGFK (N-ter) 28
7 Q8I0U7 MDVVN.....TPISD (N-ter) 29
KGRFH…..KFNDY (middle) 53
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insertions of fifty four and thirty five amino acid residues are
associated with the subunits (UniProt codes: Q8I0U7 and
Q7K6A9, respectively).
Three-dimensional model of the Pf 20S proteasome and
the Plasmodia-specific ‘large’ insert sequences in some of
the beta subunits
The quality of the Pf 20S proteasome model evaluated
using the PROCHECK program for the individual sub-
units identified >90% residues in the ‘allowed’ regions of
the Ramachandran Map suggesting the models are of
good quality. A cartoon representation of the Pf 20S
model compared with the crystal structure of the yeast
20S proteasome is shown in Figure 1(A). The overall fold
of the CP is similar to that of the yeast 20S proteasome.
The cavity on the side of the α-ring where the substrate
enters the catalytic site is shown in Figure 1(B).
The ‘large’ inserts are known to correspond to coding
regions of low complexity (LCRs) which are a feature of
many proteins in plasmodia. Although, the structure of
these inserts are not known, its function has been sug-
gested in the obstruction of immune-dominant epitopes
and the presentation of ‘non-sense’ epitopes that lead to
an inefficient antibody response (Mordmüller et al. 2006).
Our model of the Pf 20S proteasome suggests that these
‘large’ inserts are distant from the catalytic sites and are
not likely to interfere with catalytic activity. Our observa-
tions are consistent with earlier predictions that suggest
that the structural integrity and protease function seem
not to be affected due to the ‘large’ inserts (Mordmüller
et al. 2006). Experimental studies aimed at truncating the
‘large’ inserts and re-design of the β1 and β7 subunits of
the Pf 20S proteasome guided by the equivalent yeast 20S
proteasome subunits may provide clues to decipher their
role in the Pf 20S proteasome. Examination of the se-
quences corresponding to the β1 subunit from other plas-
modia species reveals that the ‘large’ insert is a featurecommon to all plasmodia species analyzed in this work.
The alignment of the corresponding sequences is shown
in Figure 2.
Comparison of the catalytic residues, substrate binding
pockets and residues involved in maintaining stability of
the conformation of Thr1 in yeast and Pf 20S proteasomes
The crystal structure of yeast 20S proteasome (Groll et al.
1997) revealed that the amino acid residues; Thr1, Asp17
and Lys33 are important for catalytic activity, Ser129,
Asp166, Ser169 are important for maintaining stability of
the Thr1 conformation and amino acid residues at posi-
tions; 1, 20, 31, 35, 45, 49 and 53 comprise the substrate
binding pockets for proteolytic cleavage in the β1, β2 and
β5 catalytic subunits. The alignment of the amino acid
sequences corresponding to the equivalent β1, β2 and β5
catalytic subunits in the Pf 20S proteasome relative to
yeast and bovine 20S proteasomes are shown in Figures 3
(A-C) and labeled according to the numbering in the yeast
20S proteasome crystal structure (PDB code: 2F16).
The amino acid residues in the different catalytic sub-
units of the yeast 20S proteasome and the equivalent
residues (substitutions) in the Pf 20S proteasome are
listed in Table 3.
The amino acid residues important for the catalytic ac-
tivity in yeast 20S proteasome and associated with the β1
(PDB code: 2F16_N), β2 (2F16_H) and β5 (2F16_K) sub-
units are also present in the equivalent Pf 20S proteasome
subunits, suggesting their highly conserved nature and
that these equivalent subunits in the Pf 20S proteasome
would also be associated with catalytic activity. The
catalytic subunits in yeast 20S proteasome are associated
with P1 cleavage sites of chromogenic reporter groups,
peptidylglutamyl-peptide hydrolytic (PGPH) or post-acidic
(β1), trypsin-like or post-basic (β2), chymotrypsin-like or
post-hydrophobic (β5) activities (Arendt & Hochstrasser
1997). The substitutions observed in the corresponding
subunits of the Pf 20S proteasome at positions; 22, 31 and
35 and certain additional substitutions in some of the sub-
units at positions; 20, 21, 49, 53 are likely to contribute to
the substrate specificity of the Pf 20S proteasome relative
to yeast 20S proteasome. The Pf 20S proteasome also con-
tains the novel catalytic β7 subunit identified in bovine
20S proteasome (Unno et al. 2002) as it is characterized
by the conserved N-terminal Gly-Thr1 residues observed
in the other catalytic subunits.
Comparative analysis of interactions of the bortezomib
inhibitor in the three catalytic subunits of Pf 20S
proteasome model and the crystal structure of yeast
20S proteasome
The crystal structure complex of yeast 20S proteasome




Figure 1 Schematic representation showing structural overlay of the crystal structure of yeast 20S proteasome [PDB code:1RYP]
(orange) and the Pf 20S proteasome model (yellow); (A) side-view and (B) top-view.
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Figure 2 Multiple sequence alignment corresponding to the β1 subunit sequences in Plasmodium falciparum and 5 other Plasmodium
species and the yeast 20S proteasome. The ‘large’ insert region is common to the 20S proteasomes of the Plasmodium species analyzed.
‘*’ indicates identical residues, ‘:’ indicates conservative substitutions, ‘.’ indicates >50% of residues are conserved in the alignment.
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lytic sites; β1, β2 and β5 provided the structural basis at
atomic resolution for the different in vivo binding affinities
of bortezomib for the individual subunits that are roughly
attributed to the interactions of the leucine, pyrazine and
boronate moieties (Groll et al. 2006). Our docking results
were able to successfully reproduce the binding mode of
bortezomib as observed in the crystal structure of the yeast
20S proteasome-bortezomib complex (PDB code: 2F16).
The structural overlay showing the cartoon representation
of the crystal structure of yeast 20S proteasome with bor-
tezomib inhibitor (orange) (PDB code: 2F16) and bortezo-
mib docked in the three-dimensional model of the Pf 20S
proteasome (yellow) corresponding to the β1, β2 and β5
subunits are shown in Figures 4[A,B,C], respectively.
These figures demonstrate the overall structural similarity
of the catalytic subunits in yeast and Pf 20S proteasomesand the similar binding modes of bortezomib in the
equivalent subunits. The magnified images of the docked
bortezomib inhibitor (Figures 4D, E and F) shows its bind-
ing mode in the β1, β2 and β5 subunits, respectively. The
β2 subunit of the Pf 20S proteasome is associated with a
relative displacement of the pyrazine moiety of bortezomib
(Figure 4E) compared to that in yeast 20S proteasome.
The intermolecular interaction energies obtained from
AutoDock for binding of bortezomib within the equiva-
lent catalytic subunits of yeast and Pf 20S proteasomes
are shown in Table 4.
Despite the observed substitutions in the equivalent
catalytic subunits of the Pf 20S proteasome relative to
yeast 20S proteasome, most hydrogen bond interactions
between bortezomib and yeast 20S proteasome are also
present in the models of the Pf 20S proteasome-
bortezomib complex as shown in Figures 5(A-C).
(A) (B)
(C)
Figure 3 Multiple sequence alignment corresponding to (A) β1, (B) β2 and (C) β5 subunit sequences of the yeast 20S proteasome
[PDB code:2F16], bovine 20S proteasome [PDB code:1IRU] and Pf 20S proteasome [UniProt codes]. Residue labeling is according to
PDB code:2F16.
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code:2F16, N-chain), the bortezomib inhibitor (BO2
1404) makes hydrogen bond interactions with residues
in the binding pockets involving the main-chain atoms
of Thr21, Gly47, Ala49 and side-chain atom of Thr22
and both main-chain and side-chain atoms of Thr1
(Groll et al. 2006). By comparison, all the above interac-
tions are also observed in the corresponding β1 subunit
of the Pf 20S proteasome (Figure 5A). The equivalent
hydrogen-bond interactions with bortezomib at positions
21 and 22 are also conserved despite the substitutions;
Thr21-Ser, Thr22-Ser, as serine only lacks the side-chain
C-gamma atom compared with threonine. The Ala49-Ser
mutation contributes an extra hydrogen-bond interaction
via the side-chain OG atom of serine in the Pf 20S prote-
asome β1 subunit relative to yeast 20S proteasome favor-
ing better binding interactions to bortezomib.
In the β2 subunit of the yeast 20S proteasome (PDB
code:2F16, H-chain), bortezomib (BO2 1400) makes
hydrogen bond interactions with residues in the binding
site pockets involving the main-chain atoms of Thr21,
Gly47, Ala49 and side-chain atom of Ser20 and both the
main-chain and side-chain atoms of Thr1 (Groll et al.
2006). All these interactions are also observed in thecorresponding β2 subunit of the Pf 20S proteasome
except the side-chain hydrogen-bond interaction with
bortezomib due to the Ser20-Ala substitution (Figure 5B).
Further, the side-chain hydrogen bond interactions made
by Thr22 in the β1 subunit of yeast 20S proteasome is not
observed at the equivalent position in the β2 subunit of
both yeast and Pf 20S proteasomes due to substitutions by
Gln22 and Glu22, respectively. For these reasons, the pyr-
azine moiety of bortezomib is not likely to make any inter-
action with protein residues in the β2 subunits of both
yeast and Pf 20S proteasomes. Further, the Ser20Ala sub-
stitution may contribute to the relative displacement
(weaker binding) of bortezomib in the β2 subunit of Pf
20S proteasome compared to that in the yeast 20S prote-
asome (see Figures 4E and 5E). The phenylalanine ring is
‘flipped’ relative to the other two catalytic subunits and it
has been suggested that the P2 site of bortezomib possibly
contributes to overall pharmacodynamic properties, but
not kinetics of inhibition (Groll et al. 2006). In case of the
β2 subunit of Pf 20S proteasome too, the phenylalanine
moiety is exposed to the surface and is ‘flipped’ relative to
its conformation in the β1 and β5 catalytic subunits as ob-
served in the β2 subunit of the yeast 20S proteasome. The
binding affinity of bortezomib in the β2 subunit of Pf 20S
Table 3 Amino acid residues in β1, β2, β5 catalytic subunits
in yeast 20S proteasome (PDB code: 2F16:N,H,K-chains,
respectively) and equivalent residues (substitutions) in Pf
20S proteasome associated with the catalytic sites, substrate
binding pockets, maintenance of stability of Thr1 and
interactions with the bortezomib inhibitor
Residue Number Catalytic subunits
β1 β2 β5
1 T T T
17 D D D
20 T S(A) A
21 T(S) T T(S)
22 T(S) Q(E) A(M)
31 T(S) C V
33 K K K
35 T(N) H I
45 R G M
47 G G G
49 A(S) A A
53 Q E Q(L)
129 S S S
166 D D D
169 S S S
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ing in the β2 subunit of the yeast 20S proteasome as
reflected in the relatively higher intermolecular energies
for bortezomib binding to the β2 subunit of Pf 20S pro-
teasome shown in Table 4. Moreover, it is also known
that bortezomib has least preference for the β2 subunit
in the yeast 20S proteasome (Berkers et al. 2005). The
Glu22 in β2 subunit of the Pf 20S proteasome has two
oxygen atoms (OE1, OE2) in its side-chain when com-
pared with Gln22 in yeast 20S proteasome that may be
exploited in designing suitable bortezomib analogs that
make favourable interaction with the inhibitor in the β2
subunit of Pf 20S proteasome.
Finally, in the β5 subunit of the yeast 20S proteasome
(PDB code:2F16, K-chain), bortezomib (BO2 1402) makes
hydrogen bond interactions with residues in the binding
pockets involving the main-chain Thr21, Gly47, Ala49 and
main-chain and side-chain of Thr1 (Groll et al. 2006).
These interactions are also observed in the corresponding
β5 subunit of the Pf 20S proteasome (Figure 5C). The
Thr21-Ser substitution in the β5 subunit of the Pf 20S
proteasome does not affect the hydrogen-bond interac-
tions with bortezomib. All other residues comprising the
inhibitor binding pocket remaining the same, the substitu-
tions; Ala22-Met, Gln53-Leu in the β5 subunit of the Pf20S proteasome may affect the relative chymotryptic-like
activity compared with the yeast 20S proteasome.
The preference for the affinity of bortezomib to the β5
subunit relative to the other two catalytic subunits in
yeast 20S proteasome, i.e., β5 > β1 > > β2 (Berkers et al.
2005) is reflected in the low intermolecular interaction
energy for the β5 subunit (−6.84 kcal/mol) as shown in
Table 4. In Pf 20S proteasome, however, bortezomib ap-
pears to have a preference for the β1 subunit as inferred
from the relative intermolecular interaction energies.
The observed substitutions in the β1 and β5 subunits of
the Pf 20S proteasome compared to the yeast 20S prote-
asome mentioned earlier may contribute to the relative
preference for bortezomib inhibition. Accordingly, bor-
tezomib inhibition may influence the caspase-like and
chymotryptic-like activities in Pf 20S proteasome com-
pared to that in yeast 20S proteasome. The binding
affinity of bortezomib to the β2 subunit of the Pf 20S
proteasome is least as inferred from the relative high
intermolecular interaction energy value (−1.54 kcal/mol)
possibly due to the loss of side-chain hydrogen-bond
interactions in the β2 subunit of the Pf 20S proteasome
due to Ser20Ala substitution.
In an earlier comprehensive study on the proteasome in-
hibitors against Plasmodium falciparum laboratory strains,
bortezomib inhibitory activity was observed to be low
(Kreidenweiss et al. 2008) in contrast to multiple myeloma
treatment (Rajkumar et al. 2005). Our analysis is in agree-
ment with the above experimental observations. Bortezo-
mib is capable of binding to the equivalent catalytic
subunits of the Pf 20S proteasome although relatively less
efficiently as reflected in the relatively higher intermolecu-
lar energy values for the Pf 20S proteasome shown in
Table 4. The lower efficiency of bortezomib binding in the
catalytic subunits of Pf 20S proteasome relative to yeast
20S proteasome may be due to the observed substitutions
within the bortezomib binding pockets. Also, the substitu-
tions described for the Pf 20S proteasome contribute to
the different charge patterns and overall architecture (see
Figures 5D, E and F) as observed in the yeast 20S prote-
asome (Groll et al. 2006).
The binding mode of bortezomib inhibitor is similar
to that observed in the catalytic subunits of the yeast
20S proteasome, except in the β2 subunit of the Pf 20S
proteasome where there is a relative displacement due
to the observed substitution. Therefore, the substitutions
identified in the equivalent catalytic subunits of the Pf
20S proteasome compared to the yeast 20S proteasome
may only affect the relative caspase-like, tryptic-like and
chymotryptic-like activities although bortezomib binding
may not be largely affected. The phenylalanine moiety of
bortezomib is exposed and does not make interactions
with the protein subunits also in the Pf 20S proteasome
as is observed in the yeast 20S proteasome. Our models
Figure 4 Schematic representations of the structural overlay corresponding to the crystal structure of the yeast 20S proteasome
bortezomib inhibitor complex [PDB code:2F16] (orange) and the model of the Pf 20S proteasome with docked bortezomib inhibitor
(yellow) in the catalytic sites of (A) β1, (B) β2 and (C) β5 subunits. Magnified images of the bortezomib inhibitors (in stick representation) are
shown for the above subunits in (D), (E) and (F), respectively.
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http://www.springerplus.com/content/2/1/566of the Pf 20S proteasome with bortezomib provide the
structural basis for rational design of Pf 20S proteasome
specific inhibitors.
We suggest other possible strategies for Pf 20S prote-
asome inhibition, such as, to design suitable compounds
that block interactions at the interface of α/β, α/α or
β/β subunits, as it is understood that the α and β sub-
units are formed first with subsequent formation of the
seven membered ring (Wolf & Hilt 2004). Further, the
formation of the active 20S proteasome is preceded by
the cleavage of its pro-sequence. Therefore, the structure
of the inactive catalytic subunit with the pro-sequence
bound may provide clues to designing suitable inhibitors.
As high resolution structural data for the regulatory sub-
units become available, it would provide further oppor-
tunities for the design of compounds that inhibit substrateTable 4 Intermolecular interaction energies of
Bortezomib (Velcade®) inhibitor in the catalytic subunits
of the crystal structure of yeast 20S proteasome and in
the equivalent subunits of the Pf 20S proteasome model






Pf_Beta5 −4.29recognition or molecular events that guide the entry of
the substrate towards the catalytic core. The availability
of a number of other proteasome inhibitors (Kreidenweiss
et al. 2008; Buac et al. 2013) provides an opportunity to
carry out docking studies with these compounds in the
three-dimensional models of the Pf 20S proteasome that
are relevant for malaria therapeutics.
Finally, another observation that we have made, al-
though not related to the Pf 20S proteasome catalytic
sites is the comparison of sequences of the 20S protea-
somes of bovine, yeast and Pf with regard to the
Nuclear Localization Signal (NLS). The bovine 20S pro-
teasome contains a sequence motif [X-X-K-K(R)-X-K
(R)] associated with the α1 - α4 subunits needed for its
import into nucleus by the importin-α receptor (Unno
et al. 2002). This sequence motif is not present in the
equivalent α subunits of the Pf and yeast 20S protea-
somes as shown in Table 5.Conclusions
The three-dimensional model of the Pf 20S proteasome
complexed with the bortezomib inhibitor supports previ-
ous experimental studies that demonstrate bortezomib in-
hibition of the Pf 20S proteasome and further elucidates
its binding mode within the catalytic subunits. The affinity
for bortezomib binding to the Pf laboratory strains is
known to be low in contrast to binding eukaryotic 20S
proteasome as evinced from multiple myeloma treatment
and the relative intermolecular interaction energies
Figure 5 Structural superposition of the yeast 20S proteasome - bortezomib inhibitor crystal structure complex [PDB code:2F16] and Pf
20S proteasome – bortezomib model showing inter-molecular hydrogen bond interactions and residues close to the inhibitor defined by a
4.0 Å cut-off value in (A) β1, (B) β2 and (C) β5 subunits. The electrostatic charge surface (red;electronegative, blue;electropositive) for the Pf 20S
proteasome model with bound bortezomib for the above subunits are shown in figures (D), (E) and (F), respectively.
Sridhar et al. SpringerPlus 2013, 2:566 Page 10 of 11
http://www.springerplus.com/content/2/1/566obtained from our docking studies is consistent with
the above results. Further, our docking analysis suggests
a relative preference for bortezomib binding to the β1
subunit in the Pf 20S proteasome. The amino acid resi-
due substitutions identified within the catalytic subunitsTable 5 Nuclear localization signal [X-X-K-K(R)-X-K(R)] in
bovine 20S proteasome and equivalent amino acid
sequence in Pf and yeast 20S proteasomes
Alpha subunits Bovine Pf Yeast
1 LEKKVK(179–184) LERLLE LENHFK
2 TEKKQK(47–52) TEKKSP TEKKSS
3 REKKEK(249–254) ———— EEADED
4 EKKKQK(240–245) NEQNE- QEQDKKare useful candidates for evaluating the structure-
activity relationship of the Pf 20S proteasome. Our
models provide the structural basis for rational design
of Pf 20S proteasome-specific catalytic site inhibitory
compounds among other strategies that exploit struc-
tural information for the purpose of drug design.
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